Trial Profile

A Single Arm Phase II Trial of Trastuzumab Deruxtecan in Patients With Gastrooesophageal Adenocarcinoma Cancer Who Are ctDNA and HER2 Positive

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary)
Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
Focus Therapeutic Use
Acronyms DECIPHER

Most Recent Events

21 Jan 2025 According to a Natera media release, company will present a poster of this study at the American Society of Clinical Oncologys Gastrointestinal Cancers Symposium (ASCO GI) taking place Jan. 23-25, 2025 in San Francisco, CA.
17 Apr 2024 Status changed from not yet recruiting to recruiting.
17 Apr 2024 Planned End Date changed from 28 Feb 2028 to 30 Apr 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com